Elevated portal vein drug levels of sirolimus and tacrolimus in islet transplant recipients: local immunosuppression or islet toxicity?

• Published in: Transplantation Vol. 76; no. 11; p. 1623
• Main Authors: Desai, Niraj M, Goss, John A, Deng, Shaoping, Wolf, Bryan A, Markmann, Eileen, Palanjian, Maral, Shock, Angela P, Feliciano, Sue, Brunicardi, F Charles, Barker, Clyde F, Naji, Ali, Markmann, James F
• Format: Journal Article
• Language: English
• Published: United States 15.12.2003
• Subjects: Humans; Immunosuppression - methods; Immunosuppressive Agents - blood; Immunosuppressive Agents - pharmacokinetics; Immunosuppressive Agents - therapeutic use; Islets of Langerhans - pathology; Islets of Langerhans Transplantation - immunology; Portal System; Portal Vein - physiology; Regression Analysis; Sirolimus - blood; Sirolimus - pharmacokinetics; Sirolimus - therapeutic use
• ISSN: 0041-1337
• DOI: 10.1097/01.TP.0000081043.23751.81

The recent success of islet transplantation using the Edmonton protocol involved the use of sirolimus, tacrolimus, and daclizumab for immunosuppression. Islets were infused into the portal circulation after transhepatic access. This protocol provided a unique opportunity to measure sirolimus and tacrolimus levels from the portal vein and compare them to systemic venous levels. A total of 11 portal venous samples with a corresponding peripheral venous sample were obtained from patients undergoing a first or second islet infusion and medication levels were obtained on both types of specimens. The portal-to-systemic drug level ratio ranged from 0.95 to 2.71 for sirolimus and 1.0 to 3.12 for tacrolimus. Given the potential toxicity of these agents to islets, the findings in this study may have implications for designing the next generation of immunosuppressive protocols for islet transplantation.